Actinium Pharmaceuticals, Inc.

As of May 15, 2023, Actinium Pharmaceuticals, Inc. is considered overvalued with significant financial concerns, reflected in its low valuation score of -0.9802, a Price to Book Value of 2.22, and a poor one-year return of -79.21%, making it a potentially unviable investment compared to its peers.

As of June 17, 2025, the trend is mildly bullish due to positive daily moving averages and weekly MACD signals, but caution is advised as monthly indicators remain bearish, indicating potential long-term weaknesses.

As of March 2022, the management team of Actinium Pharmaceuticals, Inc. includes Mr. Sandesh Seth (Chairman and CEO), Dr. C. David Nicholson (Lead Independent Director), and Independent Directors Dr. Jeffrey Chell, Dr. Ajit Shetty, and Mr. Richard Steinhart. They oversee the company's strategic direction and governance.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. As of March 2025, it has a market cap of $44.61 million and reported a net loss of $16 million.

As of Jun 18, Actinium Pharmaceuticals, Inc. has a market capitalization of 44.61 million, with net sales of 0.00 million and a net profit of -45.51 million over the latest four quarters. Shareholder's funds are 32.76 million, and total assets are 76.90 million.